Anna Margolina, PhD is being referenced as one of the leading scientists involved in the research and development of GHK-CU
What To Watch Next The next phase of the story is not just more numbers
While semaglutide offers benefits in terms of glycaemic control, weight and cardiovascular risk, this study confirms that, for T2D patients with obesity, the 2 mg/week dose is the highest that can be justified for glycaemic management
A Strength of recommendation (SOR) A Good-quality patient-oriented evidence B Inconsistent or limited-quality patient-oriented evidence C Consensus, usual practice, opinion, disease-oriented evidence, case series The "Standards of Medical Care in Diabetes" guidelines published in 2015 by the American Diabetes Association (ADA) state that metformin is the preferred initial pharmacotherapy for managing type 2 diabetes
Test your knowledge + In fact, it was a friend who gave me the idea
In the present review, we describe the epidemiologic evidence that links cholecystectomy to MetS